Skip to Content
Merck

G2295

Glimepiride

≥98% (HPLC), insulin secretagogue, solid

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

50 MG

€221.00

250 MG

€795.00

€221.00

Estimated to ship onDecember 22, 2025Details

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C24H34N4O5S
CAS Number:
93479-97-1
Molecular Weight:
490.62
UNSPSC Code:
12352200
PubChem Substance ID:
24895093
NACRES:
NA.77
MDL number:
MFCD00878417

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Glimepiride, ≥98% (HPLC), solid

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

assay

≥98% (HPLC)

form

solid

color

white

mp

212.2-214.5 °C

solubility

DMSO: >10 mg/mL

originator

Sanofi Aventis

storage temp.

room temp

Quality Level

100

Gene Information

human ... ABCC8(6833), KCNJ1(3758), KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PHR1617BP1144BP1141
Glimepiride ≥98% (HPLC), solid

Sigma-Aldrich

G2295

Glimepiride

Glimepiride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1617

Glimepiride

Glimepiride British Pharmacopoeia (BP) Reference Standard

BP1144

Glimepiride

Glimepiride for system suitability British Pharmacopoeia (BP) Reference Standard

BP1141

Glimepiride for system suitability

form

solid

form

-

form

solid

form

solid

assay

≥98% (HPLC)

assay

-

assay

-

assay

-

Quality Level

100

Quality Level

300

Quality Level

-

Quality Level

-

storage temp.

room temp

storage temp.

2-30°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: >10 mg/mL

solubility

-

solubility

-

solubility

-

originator

Sanofi Aventis

originator

-

originator

-

originator

-

Biochem/physiol Actions

Potent blocker of cardiac KATP channels.
Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.
Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.[1]

Application

Glimepiride has been used:
  • as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)[2]
  • as a sulfonylurea ATP-sensitive potassium channel (KATP) channel inhibitor in breast cancer MDA-MB-231 cells[3]
  • in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion[4]

Glimepiride is currently used to treat type 2 diabetes.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

Glimepiride is a class II biopharmaceutical[1] second-generation sulfonylurea.[5]

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000443914
0000443912
0000443914
0000443912
0000425711

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Li-Ping Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)
By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This
A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG
Tiwari A, et al.
International Journal of Advanced Research , 4, 920-927 (2016)
W Rathmann et al.
Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)
To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;
William T Cefalu et al.
Lancet (London, England), 382(9896), 941-950 (2013-07-16)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with
Mitsuyoshi Takahara et al.
Endocrine journal, 59(12), 1131-1136 (2012-08-02)
We retrospectively investigated the effect of adding dipeptidyl peptidase-4 (DPP-4) inhibitor and tapering sulfonylurea on blood glucose fluctuation in Asian patients with type 2 diabetes mellitus under basal-supported oral therapy (BOT). We recruited twenty-two consecutive Japanese patients with type 2
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service